English

PEREGRINE PHARMACEUTICALS INC

EDGAR

CDMO Quarterly report (10-Q) · filed 2024-12-10

171 filing records in this dataset, filed from 1995-09-14 to 2024-12-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

33.5 million USD

2025 Q2 · USD

Exact inputs and evidence

Revenue: 33482000 USD Source

Operating margin

-37.72%

2025 Q2 · %

Exact inputs and evidence

Operating Income: -12631000 USD Source
Revenue: 33482000 USD Source

Operating cash flow

3.99 million USD

2025 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 314000 USD Source
Operating Cash Flow: -3680000 USD Source

Free cash flow

547 thousand USD

2025 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 314000 USD Source
Operating Cash Flow: -3680000 USD Source
Capital Expenditure: 4758000 USD Source
Capital Expenditure: 1311000 USD Source

Cash and cash equivalents: 33.4 million USD 2024-10-31 Source
Exact value

33415000 USD
Long-term debt including current maturities: 52.9 million USD 2024-10-31 Source
Exact value

52873000 USD
Shares outstanding: 64 million shares 2024-10-31 Source
Exact value

63956000 shares

Reported share-count change

1.14% · 722 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

63234000 shares · 2023-10-31· Source
63956000 shares · 2024-10-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

150 million USD

2023-11-01 – 2024-10-31

Exact inputs and evidence

Revenue: 33815000 USD · 2023-11-01 – 2024-01-31 Source
Revenue: 139911000 USD · 2023-05-01 – 2024-04-30 Source
Revenue: 96936000 USD · 2023-05-01 – 2024-01-31 Source
Revenue: 40173000 USD · 2024-05-01 – 2024-07-31 Source
Revenue: 33482000 USD · 2024-08-01 – 2024-10-31 Source

Net income

-152 million USD

2023-11-01 – 2024-10-31

Exact inputs and evidence

Net income: -6006000 USD · 2023-11-01 – 2024-01-31 Source
Net income: -140753000 USD · 2023-05-01 – 2024-04-30 Source
Net income: -17649000 USD · 2023-05-01 – 2024-01-31 Source
Net income: -5534000 USD · 2024-05-01 – 2024-07-31 Source
Net income: -17406000 USD · 2024-08-01 – 2024-10-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-12-10.

Financial data available through: 2024-04-30.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2024-04-30
Operating income: 11 of 11 periods available· newest 2024-04-30
Net income: 11 of 11 periods available· newest 2024-04-30
Operating cash flow: 11 of 11 periods available· newest 2024-04-30
Capital expenditure: 11 of 11 periods available· newest 2024-04-30
Total assets: 11 of 11 periods available· newest 2024-04-30
Total liabilities: 6 of 11 periods available· newest 2024-04-30
Current assets: 11 of 11 periods available· newest 2024-04-30
Current liabilities: 11 of 11 periods available· newest 2024-04-30
Cash and cash equivalents: 11 of 11 periods available· newest 2024-04-30
Long-term debt including current maturities: 3 of 11 periods available· newest 2024-04-30
Shares outstanding: 11 of 11 periods available· newest 2024-04-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-6.3%

Prior period

USD 149.27 million

2022-05-01 – 2023-04-30
Current period

USD 139.91 million

2023-05-01 – 2024-04-30

Exact inputs and evidence

139911000 − 149266000 = -9355000 USD

149266000 USD · 2022-05-01 – 2023-04-30
Inspect prior input Prior source
139911000 USD · 2023-05-01 – 2024-04-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Year-over-year change in Revenue: -9355000 USD Concept: fundies:Revenue Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 139911000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#705864 Filing: 000168316824004610 Input fundies:Revenue: 149266000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#706463 Filing: 000168316824004610
The citation records this snapshot. The page link may show a newer release later.
Net income
-54,444.8%

Prior period

USD 259,000

2022-05-01 – 2023-04-30
Current period

−USD 140.75 million

2023-05-01 – 2024-04-30

Exact inputs and evidence

-140753000 − 259000 = -141012000 USD

259000 USD · 2022-05-01 – 2023-04-30
Inspect prior input Prior source
-140753000 USD · 2023-05-01 – 2024-04-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Year-over-year change in Net income: -141012000 USD Concept: fundies:NetIncome Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -140753000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#623097 Filing: 000168316824004610 Input fundies:NetIncome: 259000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#623473 Filing: 000168316824004610
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 23.67 million

Prior period

−USD 12.72 million

2022-05-01 – 2023-04-30
Current period

USD 10.95 million

2023-05-01 – 2024-04-30

Exact inputs and evidence

10952000 − -12722000 = 23674000 USD

-12722000 USD · 2022-05-01 – 2023-04-30
Inspect prior input Prior source
10952000 USD · 2023-05-01 – 2024-04-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Year-over-year change in Operating cash flow: 23674000 USD Concept: fundies:OperatingCashFlow Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 10952000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#644382 Filing: 000168316824004610 Input fundies:OperatingCashFlow: -12722000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#644736 Filing: 000168316824004610
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-59.1%

Prior period

USD 77.8 million

2022-05-01 – 2023-04-30
Current period

USD 31.81 million

2023-05-01 – 2024-04-30

Exact inputs and evidence

31805000 − 77803000 = -45998000 USD

77803000 USD · 2022-05-01 – 2023-04-30
Inspect prior input Prior source
31805000 USD · 2023-05-01 – 2024-04-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Year-over-year change in Capital expenditure: -45998000 USD Concept: fundies:CapitalExpenditure Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 31805000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647035 Filing: 000168316824004610 Input fundies:CapitalExpenditure: 77803000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647497 Filing: 000168316824004610
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2023-05-01 – 2024-04-30

Revenue USD 139.91 million 100% of revenue
Cost of revenue USD 132.59 million 95% of revenue
Operating expenses USD 26 million 19% of revenue
Operating income −USD 18.68 million −13% of revenue
Tax, interest and other Derived USD 122.08 million 87% of revenue
Net income −USD 140.75 million −101% of revenue

Cash

Operating cash flow USD 10.95 million 7.8% of revenue
Capital expenditure USD 31.81 million 23% of revenue
Free cash flow Derived −USD 20.85 million −15% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Operating loss: operating costs were 289% of revenue.
2016 Net loss: net income was −125% of revenue.
2017 Net loss: net income was −49% of revenue.
2018 Operating loss: operating costs were 138% of revenue.
2019 Operating loss: operating costs were 110% of revenue.
2020 Operating loss: operating costs were 118% of revenue.
2021 12%87%
2022 Net income was higher than operating income, so the split is not drawn.
2023 98%
2024 Operating loss: operating costs were 113% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2014-05-01 – 2015-04-30	26781000	77280000 Derived	-50499000	-141000 Derived	-50358000	-45066000 Derived	Source 2014-05-01 – 2015-04-30: 26781000 USD Inspect Revenue Open source 2014-05-01 – 2015-04-30: -50499000 USD Inspect Operating Income Open source 2014-05-01 – 2015-04-30: -50358000 USD Inspect Net Income Open source 2014-05-01 – 2015-04-30: -36019000 USD Inspect Operating Cash Flow Open source 2014-05-01 – 2015-04-30: 9047000 USD Inspect Capital Expenditure Open source
2016 2015-05-01 – 2016-04-30	44357000	40870000 Derived	3487000	59139000 Derived	-55652000	-48469000 Derived	Source 2015-05-01 – 2016-04-30: 44357000 USD Inspect Revenue Open source 2015-05-01 – 2016-04-30: 3487000 USD Inspect Operating Income Open source 2015-05-01 – 2016-04-30: -55652000 USD Inspect Net Income Open source 2015-05-01 – 2016-04-30: -39591000 USD Inspect Operating Cash Flow Open source 2015-05-01 – 2016-04-30: 8878000 USD Inspect Capital Expenditure Open source
2017 2016-05-01 – 2017-04-30	57630000	56338000 Derived	1292000	29451000 Derived	-28159000	-42796000 Derived	Source 2016-05-01 – 2017-04-30: 57630000 USD Inspect Revenue Open source 2016-05-01 – 2017-04-30: 1292000 USD Inspect Operating Income Open source 2016-05-01 – 2017-04-30: -28159000 USD Inspect Net Income Open source 2016-05-01 – 2017-04-30: -39169000 USD Inspect Operating Cash Flow Open source 2016-05-01 – 2017-04-30: 3627000 USD Inspect Capital Expenditure Open source
2018 2017-05-01 – 2018-04-30	53621000	74259000 Derived	-20638000	1175000 Derived	-21813000	-29785000 Derived	Source 2017-05-01 – 2018-04-30: 53621000 USD Inspect Revenue Open source 2017-05-01 – 2018-04-30: -20638000 USD Inspect Operating Income Open source 2017-05-01 – 2018-04-30: -21813000 USD Inspect Net Income Open source 2017-05-01 – 2018-04-30: -25992000 USD Inspect Operating Cash Flow Open source 2017-05-01 – 2018-04-30: 3793000 USD Inspect Capital Expenditure Open source
2019 2018-05-01 – 2019-04-30	53603000	59225000 Derived	-5622000	-1407000 Derived	-4215000	-13097000 Derived	Source 2018-05-01 – 2019-04-30: 53603000 USD Inspect Revenue Open source 2018-05-01 – 2019-04-30: -5622000 USD Inspect Operating Income Open source 2018-05-01 – 2019-04-30: -4215000 USD Inspect Net Income Open source 2018-05-01 – 2019-04-30: -11595000 USD Inspect Operating Cash Flow Open source 2018-05-01 – 2019-04-30: 1502000 USD Inspect Capital Expenditure Open source
2020 2019-05-01 – 2020-04-30	59702000	70642000 Derived	-10940000	-474000 Derived	-10466000	2015000 Derived	Source 2019-05-01 – 2020-04-30: 59702000 USD Inspect Revenue Open source 2019-05-01 – 2020-04-30: -10940000 USD Inspect Operating Income Open source 2019-05-01 – 2020-04-30: -10466000 USD Inspect Net Income Open source 2019-05-01 – 2020-04-30: 5827000 USD Inspect Operating Cash Flow Open source 2019-05-01 – 2020-04-30: 3812000 USD Inspect Capital Expenditure Open source
2021 2020-05-01 – 2021-04-30	95868000	83625000 Derived	12243000	1031000 Derived	11212000	21318000 Derived	Source 2020-05-01 – 2021-04-30: 95868000 USD Inspect Revenue Open source 2020-05-01 – 2021-04-30: 12243000 USD Inspect Operating Income Open source 2020-05-01 – 2021-04-30: 11212000 USD Inspect Net Income Open source 2020-05-01 – 2021-04-30: 31182000 USD Inspect Operating Cash Flow Open source 2020-05-01 – 2021-04-30: 9864000 USD Inspect Capital Expenditure Open source
2022 2021-05-01 – 2022-04-30	119597000	104175000 Derived	15422000	-112250000 Derived	127672000	-46946000 Derived	Source 2021-05-01 – 2022-04-30: 119597000 USD Inspect Revenue Open source 2021-05-01 – 2022-04-30: 15422000 USD Inspect Operating Income Open source 2021-05-01 – 2022-04-30: 127672000 USD Inspect Net Income Open source 2021-05-01 – 2022-04-30: 9465000 USD Inspect Operating Cash Flow Open source 2021-05-01 – 2022-04-30: 56411000 USD Inspect Capital Expenditure Open source
2023 2022-05-01 – 2023-04-30	149266000	145665000 Derived	3601000	3342000 Derived	259000	-90525000 Derived	Source 2022-05-01 – 2023-04-30: 149266000 USD Inspect Revenue Open source 2022-05-01 – 2023-04-30: 3601000 USD Inspect Operating Income Open source 2022-05-01 – 2023-04-30: 259000 USD Inspect Net Income Open source 2022-05-01 – 2023-04-30: -12722000 USD Inspect Operating Cash Flow Open source 2022-05-01 – 2023-04-30: 77803000 USD Inspect Capital Expenditure Open source
2024 2023-05-01 – 2024-04-30	139911000	158589000 Derived	-18678000	122075000 Derived	-140753000	-20853000 Derived	Source 2023-05-01 – 2024-04-30: 139911000 USD Inspect Revenue Open source 2023-05-01 – 2024-04-30: -18678000 USD Inspect Operating Income Open source 2023-05-01 – 2024-04-30: -140753000 USD Inspect Net Income Open source 2023-05-01 – 2024-04-30: 10952000 USD Inspect Operating Cash Flow Open source 2023-05-01 – 2024-04-30: 31805000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 139.9M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-04-30	Revenue	26781000	Revenue: 26781000 Open source
20162016-04-30	Revenue	44357000	Revenue: 44357000 Open source
20172017-04-30	Revenue	57630000	Revenue: 57630000 Open source
20182018-04-30	Revenue	53621000	Revenue: 53621000 Open source
20192019-04-30	Revenue	53603000	Revenue: 53603000 Open source
20202020-04-30	Revenue	59702000	Revenue: 59702000 Open source
20212021-04-30	Revenue	95868000	Revenue: 95868000 Open source
20222022-04-30	Revenue	119597000	Revenue: 119597000 Open source
20232023-04-30	Revenue	149266000	Revenue: 149266000 Open source
20242024-04-30	Revenue	139911000	Revenue: 139911000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-6.3% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-04-30	Year over year	19.6%	Revenue: 26781000 Open source Revenue: 22401000 Open source
20162016-04-30	Year over year	65.6%	Revenue: 44357000 Open source Revenue: 26781000 Open source
20172017-04-30	Year over year	29.9%	Revenue: 57630000 Open source Revenue: 44357000 Open source
20182018-04-30	Year over year	-7%	Revenue: 53621000 Open source Revenue: 57630000 Open source
20192019-04-30	Year over year	-0%	Revenue: 53603000 Open source Revenue: 53621000 Open source
20202020-04-30	Year over year	11.4%	Revenue: 59702000 Open source Revenue: 53603000 Open source
20212021-04-30	Year over year	60.6%	Revenue: 95868000 Open source Revenue: 59702000 Open source
20222022-04-30	Year over year	24.8%	Revenue: 119597000 Open source Revenue: 95868000 Open source
20232023-04-30	Year over year	24.8%	Revenue: 149266000 Open source Revenue: 119597000 Open source
20242024-04-30	Year over year	-6.3%	Revenue: 139911000 Open source Revenue: 149266000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -13.3% 2024

Net margin -100.6% 2024

Free cash flow margin -14.9% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-04-30	Operating margin	-188.6%	Operating Income: -50499000 Open source Revenue: 26781000 Open source
20162016-04-30	Operating margin	7.9%	Operating Income: 3487000 Open source Revenue: 44357000 Open source
20172017-04-30	Operating margin	2.2%	Operating Income: 1292000 Open source Revenue: 57630000 Open source
20182018-04-30	Operating margin	-38.5%	Operating Income: -20638000 Open source Revenue: 53621000 Open source
20192019-04-30	Operating margin	-10.5%	Operating Income: -5622000 Open source Revenue: 53603000 Open source
20202020-04-30	Operating margin	-18.3%	Operating Income: -10940000 Open source Revenue: 59702000 Open source
20212021-04-30	Operating margin	12.8%	Operating Income: 12243000 Open source Revenue: 95868000 Open source
20222022-04-30	Operating margin	12.9%	Operating Income: 15422000 Open source Revenue: 119597000 Open source
20232023-04-30	Operating margin	2.4%	Operating Income: 3601000 Open source Revenue: 149266000 Open source
20242024-04-30	Operating margin	-13.3%	Operating Income: -18678000 Open source Revenue: 139911000 Open source
20152015-04-30	Net margin	-188%	Net Income: -50358000 Open source Revenue: 26781000 Open source
20162016-04-30	Net margin	-125.5%	Net Income: -55652000 Open source Revenue: 44357000 Open source
20172017-04-30	Net margin	-48.9%	Net Income: -28159000 Open source Revenue: 57630000 Open source
20182018-04-30	Net margin	-40.7%	Net Income: -21813000 Open source Revenue: 53621000 Open source
20192019-04-30	Net margin	-7.9%	Net Income: -4215000 Open source Revenue: 53603000 Open source
20202020-04-30	Net margin	-17.5%	Net Income: -10466000 Open source Revenue: 59702000 Open source
20212021-04-30	Net margin	11.7%	Net Income: 11212000 Open source Revenue: 95868000 Open source
20222022-04-30	Net margin	106.8%	Net Income: 127672000 Open source Revenue: 119597000 Open source
20232023-04-30	Net margin	0.2%	Net Income: 259000 Open source Revenue: 149266000 Open source
20242024-04-30	Net margin	-100.6%	Net Income: -140753000 Open source Revenue: 139911000 Open source
20152015-04-30	Free cash flow margin	-168.3%	Revenue: 26781000 Open source Operating Cash Flow: -36019000 Open source Capital Expenditure: 9047000 Open source
20162016-04-30	Free cash flow margin	-109.3%	Revenue: 44357000 Open source Operating Cash Flow: -39591000 Open source Capital Expenditure: 8878000 Open source
20172017-04-30	Free cash flow margin	-74.3%	Revenue: 57630000 Open source Operating Cash Flow: -39169000 Open source Capital Expenditure: 3627000 Open source
20182018-04-30	Free cash flow margin	-55.5%	Revenue: 53621000 Open source Operating Cash Flow: -25992000 Open source Capital Expenditure: 3793000 Open source
20192019-04-30	Free cash flow margin	-24.4%	Revenue: 53603000 Open source Operating Cash Flow: -11595000 Open source Capital Expenditure: 1502000 Open source
20202020-04-30	Free cash flow margin	3.4%	Revenue: 59702000 Open source Operating Cash Flow: 5827000 Open source Capital Expenditure: 3812000 Open source
20212021-04-30	Free cash flow margin	22.2%	Revenue: 95868000 Open source Operating Cash Flow: 31182000 Open source Capital Expenditure: 9864000 Open source
20222022-04-30	Free cash flow margin	-39.3%	Revenue: 119597000 Open source Operating Cash Flow: 9465000 Open source Capital Expenditure: 56411000 Open source
20232023-04-30	Free cash flow margin	-60.6%	Revenue: 149266000 Open source Operating Cash Flow: -12722000 Open source Capital Expenditure: 77803000 Open source
20242024-04-30	Free cash flow margin	-14.9%	Revenue: 139911000 Open source Operating Cash Flow: 10952000 Open source Capital Expenditure: 31805000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 11M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-04-30	Operating cash flow	-36019000	Operating Cash Flow: -36019000 Open source
20162016-04-30	Operating cash flow	-39591000	Operating Cash Flow: -39591000 Open source
20172017-04-30	Operating cash flow	-39169000	Operating Cash Flow: -39169000 Open source
20182018-04-30	Operating cash flow	-25992000	Operating Cash Flow: -25992000 Open source
20192019-04-30	Operating cash flow	-11595000	Operating Cash Flow: -11595000 Open source
20202020-04-30	Operating cash flow	5827000	Operating Cash Flow: 5827000 Open source
20212021-04-30	Operating cash flow	31182000	Operating Cash Flow: 31182000 Open source
20222022-04-30	Operating cash flow	9465000	Operating Cash Flow: 9465000 Open source
20232023-04-30	Operating cash flow	-12722000	Operating Cash Flow: -12722000 Open source
20242024-04-30	Operating cash flow	10952000	Operating Cash Flow: 10952000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -20.9M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-04-30	Free cash flow	-45066000	Operating Cash Flow: -36019000 Open source Capital Expenditure: 9047000 Open source
20162016-04-30	Free cash flow	-48469000	Operating Cash Flow: -39591000 Open source Capital Expenditure: 8878000 Open source
20172017-04-30	Free cash flow	-42796000	Operating Cash Flow: -39169000 Open source Capital Expenditure: 3627000 Open source
20182018-04-30	Free cash flow	-29785000	Operating Cash Flow: -25992000 Open source Capital Expenditure: 3793000 Open source
20192019-04-30	Free cash flow	-13097000	Operating Cash Flow: -11595000 Open source Capital Expenditure: 1502000 Open source
20202020-04-30	Free cash flow	2015000	Operating Cash Flow: 5827000 Open source Capital Expenditure: 3812000 Open source
20212021-04-30	Free cash flow	21318000	Operating Cash Flow: 31182000 Open source Capital Expenditure: 9864000 Open source
20222022-04-30	Free cash flow	-46946000	Operating Cash Flow: 9465000 Open source Capital Expenditure: 56411000 Open source
20232023-04-30	Free cash flow	-90525000	Operating Cash Flow: -12722000 Open source Capital Expenditure: 77803000 Open source
20242024-04-30	Free cash flow	-20853000	Operating Cash Flow: 10952000 Open source Capital Expenditure: 31805000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

81.9% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2015-04-30	Liabilities / assets	Not reported	Total Assets: 97464000 Open source
2016-04-30	Liabilities / assets	Not reported	Total Assets: 109043000 Open source
2017-04-30	Liabilities / assets	Not reported	Total Assets: 118112000 Open source
2018-04-30	Liabilities / assets	Not reported	Total Assets: 95760000 Open source
20192019-04-30	Liabilities / assets	32.3%	Total Liabilities: 25327000 Open source Total Assets: 78395000 Open source
20202020-04-30	Liabilities / assets	61.1%	Total Liabilities: 65724000 Open source Total Assets: 107620000 Open source
20212021-04-30	Liabilities / assets	70.7%	Total Liabilities: 187774000 Open source Total Assets: 265510000 Open source
20222022-04-30	Liabilities / assets	59.4%	Total Liabilities: 255317000 Open source Total Assets: 429843000 Open source
20232023-04-30	Liabilities / assets	58.1%	Total Liabilities: 262398000 Open source Total Assets: 451567000 Open source
20242024-04-30	Liabilities / assets	81.9%	Total Liabilities: 275668000 Open source Total Assets: 336557000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.47× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-04-30	Current assets / current liabilities	2.16×	Current Assets: 80523000 Open source Current Liabilities: 37331000 Open source
20162016-04-30	Current assets / current liabilities	1.42×	Current Assets: 81808000 Open source Current Liabilities: 57574000 Open source
20172017-04-30	Current assets / current liabilities	1.43×	Current Assets: 89874000 Open source Current Liabilities: 62931000 Open source
20182018-04-30	Current assets / current liabilities	1.79×	Current Assets: 67827000 Open source Current Liabilities: 37863000 Open source
20192019-04-30	Current assets / current liabilities	2.22×	Current Assets: 51318000 Open source Current Liabilities: 23162000 Open source
20202020-04-30	Current assets / current liabilities	1.34×	Current Assets: 59763000 Open source Current Liabilities: 44480000 Open source
20212021-04-30	Current assets / current liabilities	2.93×	Current Assets: 207804000 Open source Current Liabilities: 70936000 Open source
20222022-04-30	Current assets / current liabilities	2.38×	Current Assets: 180023000 Open source Current Liabilities: 75761000 Open source
20232023-04-30	Current assets / current liabilities	0.52×	Current Assets: 112451000 Open source Current Liabilities: 215146000 Open source
20242024-04-30	Current assets / current liabilities	1.47×	Current Assets: 104002000 Open source Current Liabilities: 70566000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2014-05-01 – 2015-04-30	−USD 50.36 million Exact value Exact value: -50358000 USD 2014-05-01 – 2015-04-30: -50358000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2015-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: -50358000 USD Concept: fundies:NetIncome Period: 2014-05-01 to 2015-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2015-04-30&surface=latest&period_type=duration&start=2014-05-01&unit=USD&dimensions= Input fundies:NetIncome: -50358000 USD (2014-05-01 to 2015-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316817001772/pphm-20170430.xml#109505 Filing: 000168316817001772 The citation records this snapshot. The page link may show a newer release later.	−USD 36.02 million Exact value Exact value: -36019000 USD 2014-05-01 – 2015-04-30: -36019000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2015-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: -36019000 USD Concept: fundies:OperatingCashFlow Period: 2014-05-01 to 2015-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2015-04-30&surface=latest&period_type=duration&start=2014-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36019000 USD (2014-05-01 to 2015-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316817001772/pphm-20170430.xml#228510 Filing: 000168316817001772 The citation records this snapshot. The page link may show a newer release later.	USD 9.05 million Exact value Exact value: 9047000 USD 2014-05-01 – 2015-04-30: 9047000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2015-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 9047000 USD Concept: fundies:CapitalExpenditure Period: 2014-05-01 to 2015-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2015-04-30&surface=latest&period_type=duration&start=2014-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9047000 USD (2014-05-01 to 2015-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316817001772/pphm-20170430.xml#229104 Filing: 000168316817001772 The citation records this snapshot. The page link may show a newer release later.	−USD 45.07 million Calculation and evidence -36019000 − 9047000 USD Exact free cash flow: -45066000 USD 2014-05-01 – 2015-04-30: -36019000 USD · Inspect Operating Cash Flow · Source 2014-05-01 – 2015-04-30: 9047000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2015-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -45066000 USD Concept: free-cash-flow Period: 2014-05-01 to 2015-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36019000 USD (2014-05-01 to 2015-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316817001772/pphm-20170430.xml#228510 Filing: 000168316817001772 Input fundies:CapitalExpenditure: 9047000 USD (2014-05-01 to 2015-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316817001772/pphm-20170430.xml#229104 Filing: 000168316817001772 The citation records this snapshot. The page link may show a newer release later.
2016 2015-05-01 – 2016-04-30	−USD 55.65 million Exact value Exact value: -55652000 USD 2015-05-01 – 2016-04-30: -55652000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2016-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: -55652000 USD Concept: fundies:NetIncome Period: 2015-05-01 to 2016-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2016-04-30&surface=latest&period_type=duration&start=2015-05-01&unit=USD&dimensions= Input fundies:NetIncome: -55652000 USD (2015-05-01 to 2016-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316818001961/cdmo-20180430.xml#472268 Filing: 000168316818001961 The citation records this snapshot. The page link may show a newer release later.	−USD 39.59 million Exact value Exact value: -39591000 USD 2015-05-01 – 2016-04-30: -39591000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2016-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: -39591000 USD Concept: fundies:OperatingCashFlow Period: 2015-05-01 to 2016-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2016-04-30&surface=latest&period_type=duration&start=2015-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39591000 USD (2015-05-01 to 2016-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316818001961/cdmo-20180430.xml#638036 Filing: 000168316818001961 The citation records this snapshot. The page link may show a newer release later.	USD 8.88 million Exact value Exact value: 8878000 USD 2015-05-01 – 2016-04-30: 8878000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2016-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 8878000 USD Concept: fundies:CapitalExpenditure Period: 2015-05-01 to 2016-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2016-04-30&surface=latest&period_type=duration&start=2015-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8878000 USD (2015-05-01 to 2016-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316818001961/cdmo-20180430.xml#497614 Filing: 000168316818001961 The citation records this snapshot. The page link may show a newer release later.	−USD 48.47 million Calculation and evidence -39591000 − 8878000 USD Exact free cash flow: -48469000 USD 2015-05-01 – 2016-04-30: -39591000 USD · Inspect Operating Cash Flow · Source 2015-05-01 – 2016-04-30: 8878000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2016-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -48469000 USD Concept: free-cash-flow Period: 2015-05-01 to 2016-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39591000 USD (2015-05-01 to 2016-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316818001961/cdmo-20180430.xml#638036 Filing: 000168316818001961 Input fundies:CapitalExpenditure: 8878000 USD (2015-05-01 to 2016-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316818001961/cdmo-20180430.xml#497614 Filing: 000168316818001961 The citation records this snapshot. The page link may show a newer release later.
2017 2016-05-01 – 2017-04-30	−USD 28.16 million Exact value Exact value: -28159000 USD 2016-05-01 – 2017-04-30: -28159000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2017-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: -28159000 USD Concept: fundies:NetIncome Period: 2016-05-01 to 2017-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2017-04-30&surface=latest&period_type=duration&start=2016-05-01&unit=USD&dimensions= Input fundies:NetIncome: -28159000 USD (2016-05-01 to 2017-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316819002038/cdmo-20190430.xml#109023 Filing: 000168316819002038 The citation records this snapshot. The page link may show a newer release later.	−USD 39.17 million Exact value Exact value: -39169000 USD 2016-05-01 – 2017-04-30: -39169000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2017-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: -39169000 USD Concept: fundies:OperatingCashFlow Period: 2016-05-01 to 2017-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2017-04-30&surface=latest&period_type=duration&start=2016-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39169000 USD (2016-05-01 to 2017-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316819002038/cdmo-20190430.xml#190173 Filing: 000168316819002038 The citation records this snapshot. The page link may show a newer release later.	USD 3.63 million Exact value Exact value: 3627000 USD 2016-05-01 – 2017-04-30: 3627000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2017-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 3627000 USD Concept: fundies:CapitalExpenditure Period: 2016-05-01 to 2017-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2017-04-30&surface=latest&period_type=duration&start=2016-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3627000 USD (2016-05-01 to 2017-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316819002038/cdmo-20190430.xml#190730 Filing: 000168316819002038 The citation records this snapshot. The page link may show a newer release later.	−USD 42.8 million Calculation and evidence -39169000 − 3627000 USD Exact free cash flow: -42796000 USD 2016-05-01 – 2017-04-30: -39169000 USD · Inspect Operating Cash Flow · Source 2016-05-01 – 2017-04-30: 3627000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2017-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -42796000 USD Concept: free-cash-flow Period: 2016-05-01 to 2017-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39169000 USD (2016-05-01 to 2017-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316819002038/cdmo-20190430.xml#190173 Filing: 000168316819002038 Input fundies:CapitalExpenditure: 3627000 USD (2016-05-01 to 2017-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316819002038/cdmo-20190430.xml#190730 Filing: 000168316819002038 The citation records this snapshot. The page link may show a newer release later.
2018 2017-05-01 – 2018-04-30	−USD 21.81 million Exact value Exact value: -21813000 USD 2017-05-01 – 2018-04-30: -21813000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2018-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: -21813000 USD Concept: fundies:NetIncome Period: 2017-05-01 to 2018-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2018-04-30&surface=latest&period_type=duration&start=2017-05-01&unit=USD&dimensions= Input fundies:NetIncome: -21813000 USD (2017-05-01 to 2018-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316820002138/cdmo-20200430.xml#107528 Filing: 000168316820002138 The citation records this snapshot. The page link may show a newer release later.	−USD 25.99 million Exact value Exact value: -25992000 USD 2017-05-01 – 2018-04-30: -25992000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2018-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: -25992000 USD Concept: fundies:OperatingCashFlow Period: 2017-05-01 to 2018-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2018-04-30&surface=latest&period_type=duration&start=2017-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25992000 USD (2017-05-01 to 2018-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316820002138/cdmo-20200430.xml#233457 Filing: 000168316820002138 The citation records this snapshot. The page link may show a newer release later.	USD 3.79 million Exact value Exact value: 3793000 USD 2017-05-01 – 2018-04-30: 3793000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2018-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 3793000 USD Concept: fundies:CapitalExpenditure Period: 2017-05-01 to 2018-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2018-04-30&surface=latest&period_type=duration&start=2017-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3793000 USD (2017-05-01 to 2018-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316820002138/cdmo-20200430.xml#232900 Filing: 000168316820002138 The citation records this snapshot. The page link may show a newer release later.	−USD 29.79 million Calculation and evidence -25992000 − 3793000 USD Exact free cash flow: -29785000 USD 2017-05-01 – 2018-04-30: -25992000 USD · Inspect Operating Cash Flow · Source 2017-05-01 – 2018-04-30: 3793000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2018-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -29785000 USD Concept: free-cash-flow Period: 2017-05-01 to 2018-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25992000 USD (2017-05-01 to 2018-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316820002138/cdmo-20200430.xml#233457 Filing: 000168316820002138 Input fundies:CapitalExpenditure: 3793000 USD (2017-05-01 to 2018-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316820002138/cdmo-20200430.xml#232900 Filing: 000168316820002138 The citation records this snapshot. The page link may show a newer release later.
2019 2018-05-01 – 2019-04-30	−USD 4.22 million Exact value Exact value: -4215000 USD 2018-05-01 – 2019-04-30: -4215000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2019-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: -4215000 USD Concept: fundies:NetIncome Period: 2018-05-01 to 2019-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2019-04-30&surface=latest&period_type=duration&start=2018-05-01&unit=USD&dimensions= Input fundies:NetIncome: -4215000 USD (2018-05-01 to 2019-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316821002764/cdmo-20210430.xml#136233 Filing: 000168316821002764 The citation records this snapshot. The page link may show a newer release later.	−USD 11.6 million Exact value Exact value: -11595000 USD 2018-05-01 – 2019-04-30: -11595000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2019-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: -11595000 USD Concept: fundies:OperatingCashFlow Period: 2018-05-01 to 2019-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2019-04-30&surface=latest&period_type=duration&start=2018-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11595000 USD (2018-05-01 to 2019-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316821002764/cdmo-20210430.xml#150491 Filing: 000168316821002764 The citation records this snapshot. The page link may show a newer release later.	USD 1.5 million Exact value Exact value: 1502000 USD 2018-05-01 – 2019-04-30: 1502000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2019-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 1502000 USD Concept: fundies:CapitalExpenditure Period: 2018-05-01 to 2019-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2019-04-30&surface=latest&period_type=duration&start=2018-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1502000 USD (2018-05-01 to 2019-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316821002764/cdmo-20210430.xml#151048 Filing: 000168316821002764 The citation records this snapshot. The page link may show a newer release later.	−USD 13.1 million Calculation and evidence -11595000 − 1502000 USD Exact free cash flow: -13097000 USD 2018-05-01 – 2019-04-30: -11595000 USD · Inspect Operating Cash Flow · Source 2018-05-01 – 2019-04-30: 1502000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2019-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -13097000 USD Concept: free-cash-flow Period: 2018-05-01 to 2019-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11595000 USD (2018-05-01 to 2019-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316821002764/cdmo-20210430.xml#150491 Filing: 000168316821002764 Input fundies:CapitalExpenditure: 1502000 USD (2018-05-01 to 2019-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316821002764/cdmo-20210430.xml#151048 Filing: 000168316821002764 The citation records this snapshot. The page link may show a newer release later.
2020 2019-05-01 – 2020-04-30	−USD 10.47 million Exact value Exact value: -10466000 USD 2019-05-01 – 2020-04-30: -10466000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2020-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: -10466000 USD Concept: fundies:NetIncome Period: 2019-05-01 to 2020-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2020-04-30&surface=latest&period_type=duration&start=2019-05-01&unit=USD&dimensions= Input fundies:NetIncome: -10466000 USD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316822004704/avid_i10k-043022.htm#1089323 Filing: 000168316822004704 The citation records this snapshot. The page link may show a newer release later.	USD 5.83 million Exact value Exact value: 5827000 USD 2019-05-01 – 2020-04-30: 5827000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2020-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: 5827000 USD Concept: fundies:OperatingCashFlow Period: 2019-05-01 to 2020-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2020-04-30&surface=latest&period_type=duration&start=2019-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 5827000 USD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316822004704/avid_i10k-043022.htm#608197 Filing: 000168316822004704 The citation records this snapshot. The page link may show a newer release later.	USD 3.81 million Exact value Exact value: 3812000 USD 2019-05-01 – 2020-04-30: 3812000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2020-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 3812000 USD Concept: fundies:CapitalExpenditure Period: 2019-05-01 to 2020-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2020-04-30&surface=latest&period_type=duration&start=2019-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3812000 USD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316822004704/avid_i10k-043022.htm#611025 Filing: 000168316822004704 The citation records this snapshot. The page link may show a newer release later.	USD 2.02 million Calculation and evidence 5827000 − 3812000 USD Exact free cash flow: 2015000 USD 2019-05-01 – 2020-04-30: 5827000 USD · Inspect Operating Cash Flow · Source 2019-05-01 – 2020-04-30: 3812000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2020-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: 2015000 USD Concept: free-cash-flow Period: 2019-05-01 to 2020-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 5827000 USD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316822004704/avid_i10k-043022.htm#608197 Filing: 000168316822004704 Input fundies:CapitalExpenditure: 3812000 USD (2019-05-01 to 2020-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316822004704/avid_i10k-043022.htm#611025 Filing: 000168316822004704 The citation records this snapshot. The page link may show a newer release later.
2021 2020-05-01 – 2021-04-30	USD 11.21 million Exact value Exact value: 11212000 USD 2020-05-01 – 2021-04-30: 11212000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2021-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: 11212000 USD Concept: fundies:NetIncome Period: 2020-05-01 to 2021-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2021-04-30&surface=latest&period_type=duration&start=2020-05-01&unit=USD&dimensions= Input fundies:NetIncome: 11212000 USD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824002656/avid_i10ka1-043023.htm#1385919 Filing: 000168316824002656 The citation records this snapshot. The page link may show a newer release later.	USD 31.18 million Exact value Exact value: 31182000 USD 2020-05-01 – 2021-04-30: 31182000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2021-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: 31182000 USD Concept: fundies:OperatingCashFlow Period: 2020-05-01 to 2021-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2021-04-30&surface=latest&period_type=duration&start=2020-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 31182000 USD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824002656/avid_i10ka1-043023.htm#705344 Filing: 000168316824002656 The citation records this snapshot. The page link may show a newer release later.	USD 9.86 million Exact value Exact value: 9864000 USD 2020-05-01 – 2021-04-30: 9864000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2021-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 9864000 USD Concept: fundies:CapitalExpenditure Period: 2020-05-01 to 2021-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2021-04-30&surface=latest&period_type=duration&start=2020-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9864000 USD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824002656/avid_i10ka1-043023.htm#708243 Filing: 000168316824002656 The citation records this snapshot. The page link may show a newer release later.	USD 21.32 million Calculation and evidence 31182000 − 9864000 USD Exact free cash flow: 21318000 USD 2020-05-01 – 2021-04-30: 31182000 USD · Inspect Operating Cash Flow · Source 2020-05-01 – 2021-04-30: 9864000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2021-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: 21318000 USD Concept: free-cash-flow Period: 2020-05-01 to 2021-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 31182000 USD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824002656/avid_i10ka1-043023.htm#705344 Filing: 000168316824002656 Input fundies:CapitalExpenditure: 9864000 USD (2020-05-01 to 2021-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824002656/avid_i10ka1-043023.htm#708243 Filing: 000168316824002656 The citation records this snapshot. The page link may show a newer release later.
2022 2021-05-01 – 2022-04-30	USD 127.67 million Exact value Exact value: 127672000 USD 2021-05-01 – 2022-04-30: 127672000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2022-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: 127672000 USD Concept: fundies:NetIncome Period: 2021-05-01 to 2022-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2022-04-30&surface=latest&period_type=duration&start=2021-05-01&unit=USD&dimensions= Input fundies:NetIncome: 127672000 USD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#623839 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	USD 9.47 million Exact value Exact value: 9465000 USD 2021-05-01 – 2022-04-30: 9465000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2022-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: 9465000 USD Concept: fundies:OperatingCashFlow Period: 2021-05-01 to 2022-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2022-04-30&surface=latest&period_type=duration&start=2021-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 9465000 USD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#645091 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	USD 56.41 million Exact value Exact value: 56411000 USD 2021-05-01 – 2022-04-30: 56411000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2022-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 56411000 USD Concept: fundies:CapitalExpenditure Period: 2021-05-01 to 2022-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2022-04-30&surface=latest&period_type=duration&start=2021-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 56411000 USD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647957 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	−USD 46.95 million Calculation and evidence 9465000 − 56411000 USD Exact free cash flow: -46946000 USD 2021-05-01 – 2022-04-30: 9465000 USD · Inspect Operating Cash Flow · Source 2021-05-01 – 2022-04-30: 56411000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2022-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -46946000 USD Concept: free-cash-flow Period: 2021-05-01 to 2022-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 9465000 USD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#645091 Filing: 000168316824004610 Input fundies:CapitalExpenditure: 56411000 USD (2021-05-01 to 2022-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647957 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.
2023 2022-05-01 – 2023-04-30	USD 259,000 Exact value Exact value: 259000 USD 2022-05-01 – 2023-04-30: 259000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2023-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: 259000 USD Concept: fundies:NetIncome Period: 2022-05-01 to 2023-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2023-04-30&surface=latest&period_type=duration&start=2022-05-01&unit=USD&dimensions= Input fundies:NetIncome: 259000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#623473 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	−USD 12.72 million Exact value Exact value: -12722000 USD 2022-05-01 – 2023-04-30: -12722000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2023-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: -12722000 USD Concept: fundies:OperatingCashFlow Period: 2022-05-01 to 2023-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2023-04-30&surface=latest&period_type=duration&start=2022-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12722000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#644736 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	USD 77.8 million Exact value Exact value: 77803000 USD 2022-05-01 – 2023-04-30: 77803000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2023-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 77803000 USD Concept: fundies:CapitalExpenditure Period: 2022-05-01 to 2023-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2023-04-30&surface=latest&period_type=duration&start=2022-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 77803000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647497 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	−USD 90.53 million Calculation and evidence -12722000 − 77803000 USD Exact free cash flow: -90525000 USD 2022-05-01 – 2023-04-30: -12722000 USD · Inspect Operating Cash Flow · Source 2022-05-01 – 2023-04-30: 77803000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2023-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -90525000 USD Concept: free-cash-flow Period: 2022-05-01 to 2023-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12722000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#644736 Filing: 000168316824004610 Input fundies:CapitalExpenditure: 77803000 USD (2022-05-01 to 2023-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647497 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.
2024 2023-05-01 – 2024-04-30	−USD 140.75 million Exact value Exact value: -140753000 USD 2023-05-01 – 2024-04-30: -140753000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Net Income: -140753000 USD Concept: fundies:NetIncome Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ANetIncome&period=2024-04-30&surface=latest&period_type=duration&start=2023-05-01&unit=USD&dimensions= Input fundies:NetIncome: -140753000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#623097 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	USD 10.95 million Exact value Exact value: 10952000 USD 2023-05-01 – 2024-04-30: 10952000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Operating Cash Flow: 10952000 USD Concept: fundies:OperatingCashFlow Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3AOperatingCashFlow&period=2024-04-30&surface=latest&period_type=duration&start=2023-05-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 10952000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#644382 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	USD 31.81 million Exact value Exact value: 31805000 USD 2023-05-01 – 2024-04-30: 31805000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Capital Expenditure: 31805000 USD Concept: fundies:CapitalExpenditure Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562/explain?concept=fundies%3ACapitalExpenditure&period=2024-04-30&surface=latest&period_type=duration&start=2023-05-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 31805000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647035 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.	−USD 20.85 million Calculation and evidence 10952000 − 31805000 USD Exact free cash flow: -20853000 USD 2023-05-01 – 2024-04-30: 10952000 USD · Inspect Operating Cash Flow · Source 2023-05-01 – 2024-04-30: 31805000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PEREGRINE PHARMACEUTICALS INC · 2024-04-30 PEREGRINE PHARMACEUTICALS INC (edgar:704562) Free cash flow: -20853000 USD Concept: free-cash-flow Period: 2023-05-01 to 2024-04-30 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/704562?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 10952000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#644382 Filing: 000168316824004610 Input fundies:CapitalExpenditure: 31805000 USD (2023-05-01 to 2024-04-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/704562/000168316824004610/avid_i10k-043024.htm#647035 Filing: 000168316824004610 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

171 filings · 3,848 latest values · 3,848 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000704562, 704562, CDMO, edgar:704562

Also known as AVID BIOSERVICES, INC., Avid Bioservices, Inc., PEREGRINE PHARMACEUTICALS INC, TECHNICLONE CORP/DE/, TECHNICLONE INTERNATIONAL CORP

PEREGRINE PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2023-05-01 – 2024-04-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation